Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37

OSLO, Norway, Nov. 30, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, will today host an R&D day starting at 14:00 CET/ 13:00 GMT/ 08:00 ET. The meeting will be...

from PR Newswire: https://ift.tt/3o6Pppg